Sapience Therapeutics Presents Clinical Data on Two Lead Programs, Including ST101 Oral Presentation, at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
-ST101 Phase 2 data demonstrates activation of the tumor immune microenvironment in glioblastoma (GBM)- -ST316 Phase 1 data demonstrates antagonism…
